A Clinicopathologic Characteristics and Survival Analysis of Ovarian Tumors.
- Author:
Dong Joo SUH
1
;
Jae Seong KANG
Author Information
1. Department of Obstetrics and Gynecology College of Medicine, Korea University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Borderline malignancy;
Ovarian cancer;
5-year survival rate;
Prognostic factor
- MeSH:
Carcinoma, Small Cell;
Female;
Gynecology;
Humans;
Incidence;
Korea;
Mucins;
Multivariate Analysis;
Neoplasms, Germ Cell and Embryonal;
Obstetrics;
Ovarian Neoplasms;
Ovary;
Parity;
Prognosis;
Retrospective Studies;
Survival Analysis*;
Survival Rate
- From:Korean Journal of Obstetrics and Gynecology
2004;47(10):1886-1893
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The purpose of this study was to identify the clinicopathologic characteristics, treatments and overall 5-year survival and to analyze the prognostic factors affecting the survival in patient with ovarian tumors. METHODS: We reviewed retrospectively the outcome of 116 patients with ovarian cancer and 64 patients with borderline malignant ovarian tumor, who had been treated at Department of Obstetrics and Gynecology, Korea University Anam Hospital from Jan. 1991 to Dec. 2001. Univariate and multivariate analysis for survival were conducted to test the prognostic significance of several clinicopathologic factors. RESULTS: The mean age of the patients with borderline malignant ovarian tumor was 39.9 years old, and nulliparity was most common (42.2%). Mucinous tumor was the most common histologic subtype (68.8%). The FIGO stage distribution of borderline malignancy were 89.1%, 1.6%, 9.3% for stage I, II, and III, respectively. The overall 5-year survival rate of patients with borderline malignancy was 98.4%. The mean age of the patients with ovarian cancer was 50.1 years old. The incidence of ovarian cancer according to histologic type were 74.1%, 12.9%, 11.2%, 0.9%, 0.9%, in epithelial ovarian cancer, Sex-cord stromal tumor, malignant germ cell tumor, metastatic carcinoma of the ovary, and small cell carcinoma, respectively. The FIGO stage distribution of ovarian cancer were 40.5%, 12.1%, 42.2%, 5.2% for stage I, II, III, and IV, respectively. The overall 5-year survival rate of patients with ovarian cancer was 60.9%. In multivariate analysis, FIGO stage was identified as a significant independent prognostic factor in this study. CONCLUSION: In this study, patients with borderline malignancy of the ovary have good prognosis and the overall 5-year survival rate was 98.4%. Otherwise, the overall survival rate of patients with ovarian cancer was 60.9% and the stage was most important prognostic factor.
